Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
暂无分享,去创建一个
Liang-Nian Ji | L. Ji | Z. Mao | Jin-Ming Li | Cai-Ping Tan | Cai-Ping Tan | Zong-Wan Mao | Yuan-Yuan Wang | Mei Zhao | Yi-qun Li | Xue-Yi Le | Jin-Ming Li | Mei-Xia Zhao | Yuan-Yuan Wang | Yi-Qun Li | Xue-Yi Le
[1] F. Hirayama,et al. Pharmaceutical Applications of Cyclodextrins and Their Derivatives , 2006 .
[2] J. French,et al. Rational polytherapy , 2009, Epilepsia.
[3] Jian Zhang,et al. The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines , 2007, The Prostate.
[4] Ho Sup Yoon,et al. Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.
[5] Liang-Nian Ji,et al. Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with β-cyclodextrin coupled to amino acids. , 2011, Chemistry.
[6] Zheng-Rong Lu,et al. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. , 2009, Biomaterials.
[7] J. H. Cross,et al. The surgical treatment of Landau‐Kleffner syndrome , 2009, Epilepsia.
[8] S. Mirski,et al. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.
[9] J. Riordan,et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines , 1985, Nature.
[10] Hua Su,et al. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. , 2011, Biomaterials.
[11] V. Stella,et al. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.
[12] Q. Yao,et al. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. , 2008, Expert opinion on therapeutic targets.
[13] S. Ambudkar,et al. Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges , 2008, Expert opinion on drug metabolism & toxicology.
[14] P. Choong,et al. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. , 2009, Biomaterials.
[15] Mark E. Davis,et al. Cyclodextrin-based pharmaceutics: past, present and future , 2004, Nature Reviews Drug Discovery.
[16] E. Wang,et al. HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.
[17] I. Pastan,et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[18] U. Gündüz,et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells , 2011, Cancer Chemotherapy and Pharmacology.
[19] T. Minko,et al. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. , 2008, Nanomedicine.
[20] Liang-Nian Ji,et al. Synthesis, biocompatibility and cell labeling of L-arginine-functional beta-cyclodextrin-modified quantum dot probes. , 2010, Biomaterials.
[21] Hua Ai,et al. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. , 2011, Biomaterials.
[22] D. Kerr,et al. Clinical trials of P-glycoprotein reversal in solid tumours. , 1996, European journal of cancer.
[23] V. Torchilin,et al. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. , 2009, Molecular pharmaceutics.
[24] Zongxi Li,et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.
[25] B. Szende,et al. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. , 2001, Cancer letters.
[26] P. Johnston,et al. Molecular mechanisms of drug resistance , 2005, The Journal of pathology.